Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | SAT1 | P21673 | 1/20 | 0.42 |
| ▸ | LPAR3 | Q9UBY5 | 10/20 | 0.41 |
| ▸ | LPAR2 | Q9HBW0 | 9/20 | 0.41 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16814866 | 0.94 | SAT1 (0.46) | ALDH1A1SAT1LPAR3LPAR2LPAR1 | |
| SCHEMBL16919757 | 0.92 | SAT1 (0.44) | ALDH1A1SAT1LPAR3LPAR2LPAR1 | |
| SCHEMBL16919756 | 0.88 | ALDH1A1 (0.52) | ALDH1A1SAT1LPAR3LPAR2LPAR1 | |
| SCHEMBL21553512 | 0.87 | SAT1 (0.41) | SAT1LPAR3LPAR2LPAR1 | |
| SCHEMBL26757374 | 0.84 | LPAR3 (0.40) | ALDH1A1LPAR3LPAR2LPAR1 | |
| SCHEMBL15729175 | 0.82 | SAT1 (0.52) | ALDH1A1SAT1LPAR3LPAR2LPAR1 | |
| SCHEMBL12254989 | 0.82 | SAT1 (0.52) | ALDH1A1SAT1LPAR3LPAR2LPAR1 | |
| SCHEMBL16815002 | 0.82 | LPAR3 (0.56) | ALDH1A1SAT1LPAR3LPAR2LPAR1 | |
| SCHEMBL16815020 | 0.82 | LPAR3 (0.56) | ALDH1A1SAT1LPAR3LPAR2LPAR1 | |
| SCHEMBL16815019 | 0.82 | LPAR3 (0.56) | ALDH1A1SAT1LPAR3LPAR2LPAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210054373-A1 | COMPLEX OF POLYSACCHARIDE AND DOUBLE-STRANDED RNA AND METHOD OF INHIBITING EXPRESSION OF A TARGET GENE IN A CELL | NAPAJEN PHARMA, INC. | 2021-02-25 | — | — | US | disclosed |
| US-10738304-B2 | Complex of polysaccharide and double-stranded RNA | NAPA JENOMICS CO., LTD. (JP) | 2020-08-11 | — | — | US | disclosed |
| US-20110111501-A1 | COMPLEX OF POLYSACCHARIDE AND DOUBLE-STRANDED RNA | NAPA JENOMICS CO., LTD. (JP) | 2011-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110111501-A1 | COMPLEX OF POLYSACCHARIDE AND DOUBLE-STRANDED RNA | RNGTT, MAN2A1, ADAR | ALDH1A1 3725/4885SAT1 1957/4885LPAR3 3380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.